Linda Bannister News
-
Abbott Laboratories, which plans to separate into two companies, said the tax rates of the new companies will rise in order to support the higher dividend payouts after the split. The shares fell the most in 14 months.
-
Eli Lilly & Co. said costs for Barack Obama’s health-care law were 12 times higher than one analyst estimated. That result may be the first of such surprises from pharmaceutical companies this earnings season.
-
An experimental drug from Bristol- Myers Squibb Co. helped patients with the deadliest form of skin cancer live longer in a clinical trial.
-
Pfizer Inc. investors are pushing for a spinoff of the drugmaker’s nutrition business that would command a price tag of $6.8 billion and deliver more than twice the gains of the U.S. stock market.
-
For more than three decades, scientists have dreamed of unleashing one of nature’s most powerful inventions, the human immune system, to treat cancer.
-
Bristol-Myers Squibb Co. partner Otsuka Pharmaceutical Co. won a court ruling that will prevent generic versions of the schizophrenia treatment Abilify from entering the U.S. market until April 2015.
-
Pfizer Inc. Chief Executive Officer Ian Read said he is reviewing the possible sale or spinoff of four divisions with $18.3 billion in annual revenue, led by the company’s third-biggest unit, established products.
-
Two cancer drugs from Bristol-Myers Squibb Co. could change the standard of care for patients with deadly skin and blood malignancies, according to new studies.
-
Bristol-Myers Squibb Co. , the New York-based drugmaker, said it will cut 3 percent of its global workforce, about 840 jobs, during the next six months.
-
Bristol-Myers Squibb Co. rose the most of any company in the Standard & Poor’s 500 Index after studies showed two of its cancer drugs could change the standard of care for patients with deadly skin and blood malignancies.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page